Night Sweats: Drugs That Cause or Treat Them
Night sweats, medically described as sleep hyperhidrosis, are episodes of drenching sweat during sleep severe enough to soak clothing or bedding. They have two broad origins that matter for what a reader should do next: they can be a side effect of a medication a person is already taking, or they can signal an underlying hormonal, infectious, endocrine, or malignant process that has nothing to do with any drug. The useful question is rarely "what causes night sweats" in the abstract. It is whether the timing of a specific person's symptoms lines up with a medication start or dose change, because that timeline is what separates a drug-side-effect problem (often fixable by dose adjustment or a switch) from a diagnostic problem that needs bloodwork and possibly imaging.
Several drug classes are consistently associated with night sweats in prescribing information and clinical literature: selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), opioids and opioid withdrawal, hormone-modulating cancer therapies (tamoxifen, aromatase inhibitors, GnRH agonists), insulin and sulfonylureas through nocturnal hypoglycemia, and corticosteroids at higher doses. On the treatment side, the drugs with the strongest evidence are distinct depending on the cause: systemic estrogen-based hormone therapy for menopausal vasomotor symptoms, low-dose paroxetine (marketed as Brisdelle at 7.5 mg) as the only FDA-approved non-hormonal option for that same population, and fezolinetant (marketed as Veozah), a neurokinin-3 receptor antagonist approved by the FDA in 2023 for moderate-to-severe menopausal vasomotor symptoms. Oxybutynin and gabapentin are used off-label for vasomotor symptoms with trial support behind them, but neither carries an FDA indication for this use as of this writing, and current label and coverage status should be confirmed before prescribing.
What separates drug-induced night sweats from disease-related night sweats
A practical rule: if night sweats begin within roughly two to four weeks of starting or increasing a medication known to cause sweating, and there is no fever, unintentional weight loss, palpable lymph nodes, or cough lasting more than three weeks, the medication is the leading suspect and a trial of dose adjustment or switching is reasonable before ordering an extensive workup. If any of those additional symptoms are present, or if sweats persist unchanged after the suspected drug is stopped or adjusted, the differential broadens to infection (tuberculosis, endocarditis, HIV), malignancy (particularly lymphoma), endocrine disease (hyperthyroidism, pheochromocytoma), and obstructive sleep apnea, and it should be worked up as such rather than assumed to be medication-related indefinitely.
Case literature illustrates why disease-related night sweats cannot be dismissed just because a patient is also on a drug that lists sweating as a side effect. A 2026 case report described miliary tuberculosis complicated by tuberculous vasculitis and ischemic stroke in a 16-year-old girl, a reminder that TB-related night sweats can occur in atypical age groups and with unusual complications (case report). That is a single case and does not establish incidence; it supports keeping tuberculosis on the differential for unexplained, persistent night sweats rather than supporting any specific probability estimate.
Medications commonly associated with night sweats
SSRIs and SNRIs. Serotonergic antidepressants are frequently cited as a cause of sweating, plausibly through effects on hypothalamic thermoregulation. Reported incidence varies by agent and dose in the published literature, and readers should treat any single percentage figure as an approximation pending verification against the specific trial or product label rather than a fixed rate. Venlafaxine and paroxetine at standard antidepressant doses (20-40 mg, well above the 7.5 mg dose used for vasomotor symptoms) are commonly reported as higher-incidence agents; bupropion, which lacks serotonergic activity, is generally described as lower-incidence, but individual response varies.
Hormone-modulating cancer therapies. Tamoxifen, aromatase inhibitors (anastrozole, letrozole, exemestane), and GnRH agonists (leuprolide, goserelin) all produce a low-estrogen or low-testosterone state that commonly triggers vasomotor symptoms, including night sweats, as an expected on-target effect rather than an idiosyncratic reaction. This is the single most common reason night sweats appear during cancer treatment and does not, by itself, suggest treatment failure or recurrence.
Opioids and opioid withdrawal. Active opioid use can cause sweating through central mu-receptor effects. Opioid withdrawal characteristically produces a rebound diaphoresis that is self-limited, typically resolving within one to two weeks once withdrawal has run its course, though exact timeframes vary by opioid half-life and taper approach.
Insulin and sulfonylureas. Nocturnal hypoglycemia from insulin or sulfonylureas (glipizide, glyburide, glimepiride) can present as night sweats along with tremor and tachycardia. Guideline bodies including the American Diabetes Association recommend continuous glucose monitoring or scheduled bedtime glucose checks in patients with recurrent nocturnal symptoms as part of routine diabetes care.
Other agents. Corticosteroids above roughly 10 mg/day prednisone-equivalent are commonly reported to cause sweating. Antipyretics can cause rebound sweating as a fever breaks. Tricyclic antidepressants and some PDE5 inhibitors list sweating or flushing in prescribing information for a subset of users. Any of these should be reviewed against the specific product label rather than assumed uniformly high-risk.
Hormone therapy: the most effective option for menopause-related night sweats, with tradeoffs
For night sweats driven by menopausal estrogen deficiency, systemic hormone therapy is generally regarded by menopause specialty guidance as the most effective pharmacologic option available, reducing vasomotor symptom frequency more than any non-hormonal alternative studied to date. This is a guideline-level position, not a claim from a single trial, and it comes with tradeoffs: hormone therapy is not appropriate for everyone, and decisions about it depend on age at initiation, time since menopause, personal and family history of breast cancer or venous thromboembolism, and cardiovascular risk factors. These are individualized decisions that require a clinician familiar with the patient's full history; this article cannot substitute for that assessment.
For men on androgen deprivation therapy who develop severe night sweats, low-dose progestogens (medroxyprogesterone acetate or megestrol acetate) have been studied as an off-label option, though the evidence base behind this use is considerably smaller than the evidence behind hormone therapy in menopausal women, and it should be discussed as an off-label choice rather than a standard one.
Non-hormonal options and where they fit
Not everyone can or wants to use hormone therapy. Breast cancer survivors on tamoxifen, people with a history of venous thromboembolism, and people who prefer to avoid hormones need alternatives, and several non-hormonal drugs have randomized trial support behind them for vasomotor symptoms broadly (which includes night sweats as one component of the symptom cluster, not always measured separately).
Paroxetine 7.5 mg (Brisdelle) is, as of this writing, the only non-hormonal medication with an FDA indication specifically for moderate-to-severe vasomotor symptoms of menopause; current label status should be reconfirmed at the FDA's drug database before prescribing, since indications and formulations can change. It is dosed well below standard antidepressant levels. An important interaction: paroxetine is a potent CYP2D6 inhibitor and can blunt the conversion of tamoxifen to its active metabolite, so it is generally avoided in patients taking tamoxifen; a non-interacting alternative is usually preferred in that population.
Oxybutynin, an anticholinergic drug developed for overactive bladder, has been studied off-label for vasomotor symptoms in randomized trials, with reported reductions in hot flash frequency that trial authors describe as substantial compared with placebo. It carries anticholinergic side effects (dry mouth, constipation, and, with long-term use, theoretical concern about cognitive effects in older adults) that should be weighed against benefit, particularly in patients with dementia risk factors.
Gabapentin, dosed at bedtime, has trial support for reducing vasomotor symptom frequency and has the practical advantage of sedating properties that can help with sleep onset in patients whose main complaint is nighttime sweating and waking. It is used off-label for this indication. Drowsiness and dizziness are the main tolerability limits, and dose needs adjustment in renal impairment.
Fezolinetant (Veozah), an NK3 receptor antagonist, received FDA approval in 2023 for moderate-to-severe menopausal vasomotor symptoms, based on phase 3 trial data showing meaningful reductions in symptom frequency versus placebo; exact effect sizes should be checked against the current product label rather than repeated from secondary summaries, since labeling can be updated. It does not inhibit CYP2D6, which makes it a reasonable choice for patients on tamoxifen who need a non-hormonal option.
Clonidine, an alpha-2 agonist, has long been used off-label for hot flashes with modest effect compared with the options above, limited by dry mouth, dizziness, and rebound hypertension if stopped abruptly.
A decision framework for drug-related night sweats
The single fact that changes management most is timing: did the sweating start with a new drug or dose, or has it been present regardless of medication changes? The framework below is a starting point for that conversation with a prescriber, not a substitute for one.
| Step | Question | If yes | If no / uncertain |
|---|---|---|---|
| 1. Timing | Did sweats start within 2-4 weeks of a new drug or dose increase? | Treat the drug as the leading suspect; check the product label for sweating/hyperhidrosis as a listed effect | Broaden the differential (infection, malignancy, endocrine, sleep apnea) before assuming a drug cause |
| 2. Red flags | Is there fever, weight loss, palpable nodes, or cough over 3 weeks? | Pursue urgent evaluation regardless of medication history | Continue with the medication-focused pathway |
| 3. Dose relationship | Is the effect dose-dependent (worse at higher doses, e.g., SSRIs/SNRIs)? | Discuss a supervised dose reduction with the prescriber | Consider that the drug may be a fixed, non-dose-dependent trigger (e.g., GnRH agonists, tamoxifen) |
| 4. Can the drug be changed? | Is there a same-class alternative with a lower reported sweating profile? | Discuss switching (e.g., away from paroxetine/venlafaxine toward bupropion, if clinically appropriate) | If the drug is essential and cannot be substituted (e.g., tamoxifen, ADT), move to adjunctive treatment |
| 5. Adjunctive treatment | Does the essential drug interact with CYP2D6 (as tamoxifen does)? | Favor non-CYP2D6-interacting options (fezolinetant, gabapentin, oxybutynin) over paroxetine | Standard non-hormonal or hormonal options can be considered per the patient's overall risk profile |
| 6. Persistence | Do sweats persist after 4-8 weeks despite adjustment? | Reopen the diagnostic workup; do not keep attributing symptoms to the drug indefinitely | Continue monitoring; some drug-induced sweating attenuates with time |
This is a starting checklist for a conversation with a prescriber, not a protocol for self-adjusting medication. Stopping or reducing an SSRI, SNRI, opioid, or hormone-modulating cancer drug without supervision carries its own risks, including withdrawal effects and, for cancer therapies, potential loss of disease control.
Night sweats during hormone replacement or testosterone therapy
Patients on testosterone replacement therapy sometimes report night sweats during dose titration, plausibly related to excess aromatization of testosterone to estradiol. Checking serum estradiol alongside testosterone during titration is a reasonable step for a prescriber to consider, though the exact estradiol threshold at which symptoms appear varies between individuals and is not a fixed number that applies to everyone.
In women on hormone therapy, night sweats that persist despite what should be an adequate estrogen dose can reflect an estrogen dose that is too low for that individual, or intolerance to a synthetic progestin component. Switching from oral to transdermal estradiol is sometimes used clinically to reduce first-pass hepatic metabolism and produce steadier levels, and transdermal formulations are generally preferred by menopause specialty guidance for patients with elevated triglycerides or thrombotic risk. Whether that switch is appropriate for a given patient depends on the reason for continued symptoms, which requires clinical assessment rather than self-adjustment.
GLP-1 receptor agonists (semaglutide, tirzepatide) are not commonly reported to cause night sweats directly. Rapid, substantial weight loss can alter sex hormone-binding globulin and shift free hormone levels, which is a reason clinicians may recheck hormone panels in patients on concurrent hormone therapy or testosterone replacement after significant weight change, rather than evidence that GLP-1 drugs themselves trigger sweating.
Non-drug causes that must be ruled out
Night sweats are not always about medication. Tuberculosis is the textbook infectious cause of drenching night sweats, though any chronic infection, including endocarditis and HIV, can produce the same symptom. Malignancies, particularly Hodgkin and non-Hodgkin lymphoma, cause night sweats as part of the classic "B symptoms" triad with fever and unintentional weight loss; the combination of unexplained night sweats with palpable lymphadenopathy is generally considered to warrant prompt evaluation rather than watchful waiting. Hyperthyroidism and, less commonly, pheochromocytoma and carcinoid syndrome can present with excessive sweating. Obstructive sleep apnea is associated with night sweats in a meaningful proportion of affected patients, likely through sympathetic activation during apneic episodes, and treating the apnea (for example with CPAP) typically resolves the sweating.
A separate line of evidence illustrates a related caution about generalizing findings: a 2026 network analysis examined associations between menopausal symptoms, including vasomotor symptoms, and mental health measures specifically in women with intellectual disabilities (study). That population-specific finding should not be extrapolated to menopausal women in general; it is included here as an example of why the source population for any menopause-symptom study matters before applying its conclusions broadly.
What is established, what is plausible, and what is not established
Established: hormone therapy reduces menopausal vasomotor symptom frequency more than any studied non-hormonal alternative, according to menopause specialty guidance; paroxetine 7.5 mg and fezolinetant hold FDA approval specifically for vasomotor symptoms as of this writing; SSRIs, SNRIs, opioids, hormone-modulating cancer drugs, and hypoglycemic agents are recognized causes of drug-associated sweating; night sweats combined with fever, weight loss, or lymphadenopathy warrant prompt medical evaluation for infection or malignancy.
Plausible but not firmly quantified on this page: the exact percentage reductions in hot flash frequency reported for gabapentin, oxybutynin, and fezolinetant vary across sources and should be confirmed against the specific trial or current FDA label before being used for individualized counseling, rather than treated as fixed figures.
Not established: that any single medication switch or lifestyle change will resolve night sweats for a given individual; that testosterone-related night sweats correlate with a specific estradiol cutoff applicable to all men; and that findings from small or population-specific studies (such as the intellectual disability cohort above) generalize to the broader population of people experiencing night sweats.
When to seek care rather than adjust medication at home
Persistent night sweats with unexplained weight loss, fever lasting more than a few days, new or enlarging lymph nodes, a cough lasting more than three weeks, or blood in stool or urine warrant prompt medical evaluation rather than a trial of medication adjustment. Anyone considering stopping or reducing an antidepressant, opioid, hormone therapy, or cancer treatment because of night sweats should do so with their prescriber, since abrupt changes to these drug classes carry their own risks.
Frequently asked questions
What causes night sweats?
How are night sweats diagnosed?
When should I worry about night sweats?
Can SSRIs cause night sweats?
What is the best non-hormonal medication for night sweats related to menopause?
Does testosterone replacement therapy cause night sweats?
Can night sweats be a sign of cancer?
Do GLP-1 medications cause night sweats?
Will night sweats from a medication go away on their own?
References for editorial verification. The claims above draw on menopause specialty guidance (North American Menopause Society position statements), FDA approval records for paroxetine 7.5 mg (Brisdelle) and fezolinetant (Veozah), American Diabetes Association standards of care, and published trial and case literature. Two sources are cited directly and should be checked against the linked record before publication:
- Miliary tuberculosis complicated by tuberculous vasculitis and ischemic stroke in a 16-year-old female patient: a case report, https://pubmed.ncbi.nlm.nih.gov/41606640/
- Using Network Analysis to Understand the Associations Between Menopausal Symptoms and Mental Health in Women With Intellectual Disabilities, https://pubmed.ncbi.nlm.nih.gov/41885730/
All other numeric trial results referenced in the prior draft (specific percentage reductions for gabapentin, oxybutynin, and fezolinetant; specific incidence rates for SSRI-related sweating; specific PPV figures for lymphadenopathy and lymphoma) require verification against the primary trial publications or current FDA labeling before republication, since the identifiers previously attached to them could not be confirmed as accurate for the claims made.